BCL2 and B-cell chronic lymphocytic leukemia: In parallel, the phase 3 study (CaDAnCe-302) of BGB-16673 compared to the investigator’s choice in participants with CLL/SLL previously exposed to both BTK and BCL2 inhibitors (#NCT06846671) was recently initiated.